The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.

Biotechnology

Information Technology

Life Sciences

Therapeutics

OmniAb, Inc.

Matt Foehr

Laurel Bernstein

Erika Luib

Eric Vajda

Douglas Krafte

Donna Ventura

Cia McCaffrey (She/Her)

Christel Iffland

Charles Berkman

Bill Harriman

Anil Nair

The Research and Development team at OmniAb, Inc. is responsible for leveraging the company's proprietary transgenic animals and advanced computational technologies to drive the discovery of next-generation therapeutic antibodies. This team integrates in silico sciences, medicinal chemistry, protein sciences, and antibody technologies to design and screen diverse antibody repertoires. They focus on optimizing antibody performance and developability, supporting the creation of innovative therapeutics for pharmaceutical industry partners.

Research and Development

Science and Research

Leadership Team

Research and Development

About

Team members

Other teams at OmniAb, Inc.

Science and Research

Leadership Team